$250B of U.S. Health Costs Could Be Tied to Exposure to Chemicals in Plastics
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, Jan. 16, 2024 -- Plastics exposure contributes substantially to disease costs in the United States, according to a study published online Jan. 11 in the Journal of the Endocrine Society.
Leonardo Trasande, M.D., from the NYU Grossman School of Medicine in New York City, and colleagues calculated the attributable disease burden and cost due to chemicals used in plastic materials in 2018.
The researchers identified plastic-related fractions of 97.5 percent for bisphenol A, 98 percent for di-2-ethylhexylphthalate, 100 percent for butyl phthalates and benzyl phthalates, 98 percent for polybrominated diphenylether (PBDE)-47, and 93 percent for perfluoroalkyl substances (PFAS). In a sensitivity analysis, the total estimate of plastic-attributable disease burden in 2018 ranged from $226 billion to $289 billion, with the majority of these costs arising from PBDE exposure. Additionally, an estimated $66.7 billion was due to phthalate exposure and $22.4 billion was due to PFAS exposure.
"Plastics contribute substantially to disease and associated social costs in the United States, accounting for 1.22 percent of the gross domestic product. The costs of plastic pollution will continue to accumulate as long as exposures continue at current levels," the authors write. "Actions through the Global Plastics Treaty and other policy initiatives will reduce these costs in proportion to the actual reductions in chemical exposures achieved."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-01-17 22:15
Read more
- ACAAI: Many Anaphylaxis Protocols Are Incomplete, Outdated
- Mpox Spread in Congo May Be Slowing
- Geographic Position Influences Climate Change Risk Perception of Emergency Medical Services
- Protracted Radiation Exposure Linked to Hematologic Cancer Mortality
- Shorla Oncology Announces U.S. FDA Expanded Approval of Jylamvo (methotrexate), an Oncology and Autoimmune Drug for Pediatric Indications
- 2008 to 2020 Saw More Radiologists Involved in Teaching
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions